FineMark National Bank & Trust’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$4.47M Sell
179,519
-355
-0.2% -$8.95K 0.14% 127
2025
Q3
$4.58M Sell
179,874
-4,615
-3% -$114K 0.15% 122
2025
Q2
$4.47M Sell
184,489
-1,493
-0.8% -$34.8K 0.15% 121
2025
Q1
$4.71M Sell
185,982
-10,604
-5% -$277K 0.17% 117
2024
Q4
$5.22M Sell
196,586
-15,412
-7% -$418K 0.18% 109
2024
Q3
$6.14M Sell
211,998
-4,969
-2% -$145K 0.21% 102
2024
Q2
$6.07M Sell
216,967
-35,475
-14% -$977K 0.22% 102
2024
Q1
$7.01M Sell
252,442
-19,017
-7% -$528K 0.26% 90
2023
Q4
$7.82M Sell
271,459
-18,858
-6% -$570K 0.32% 81
2023
Q3
$9.63M Sell
290,317
-17,835
-6% -$631K 0.42% 69
2023
Q2
$11.3M Sell
308,152
-196
-0.1% -$7.63K 0.46% 55
2023
Q1
$12.6M Buy
308,348
+484
+0.2% +$20.9K 0.54% 49
2022
Q4
$15.8M Sell
307,864
-20,338
-6% -$975K 0.71% 36
2022
Q3
$14.4M Sell
328,202
-5,910
-2% -$287K 0.69% 31
2022
Q2
$17.5M Sell
334,112
-5,774
-2% -$294K 0.77% 27
2022
Q1
$17.6M Sell
339,886
-87,760
-21% -$4.55M 0.7% 30
2021
Q4
$25.3M Sell
427,646
-1,013
-0.2% -$50.2K 0.96% 18
2021
Q3
$18.4M Sell
428,659
-1,865
-0.4% -$82.6K 0.78% 24
2021
Q2
$16.9M Sell
430,524
-838
-0.2% -$32.6K 0.69% 29
2021
Q1
$15.6M Sell
431,362
-2,003
-0.5% -$71.1K 0.66% 31
2020
Q4
$16M Sell
433,365
-30,517
-7% -$1.12M 0.71% 27
2020
Q3
$16.2M Sell
463,882
-545
-0.1% -$19.1K 0.78% 25
2020
Q2
$14.4M Buy
464,427
+2,714
+0.6% +$92.2K 0.8% 27
2020
Q1
$14.3M Buy
461,713
+7,145
+2% +$243K 0.9% 24
2019
Q4
$16.9M Buy
454,568
+10,082
+2% +$359K 0.85% 23
2019
Q3
$15.2M Buy
444,486
+1,204
+0.3% +$43.8K 0.81% 25
2019
Q2
$18.2M Buy
443,282
+15,066
+4% +$598K 1.01% 16
2019
Q1
$17.3M Sell
428,216
-11,753
-3% -$471K 1% 15
2018
Q4
$18.2M Buy
439,969
+5,554
+1% +$231K 1.24% 10
2018
Q3
$18.2M Sell
434,415
-15,228
-3% -$586K 1.11% 12
2018
Q2
$15.5M Buy
449,643
+10,582
+2% +$362K 0.94% 16
2018
Q1
$14.8M Buy
439,061
+6,359
+1% +$219K 0.94% 19
2017
Q4
$14.9M Buy
432,702
+6,789
+2% +$231K 0.94% 16
2017
Q3
$14.4M Sell
425,913
-5,304
-1% -$170K 0.96% 15
2017
Q2
$13.7M Buy
431,217
+9,208
+2% +$290K 0.99% 13
2017
Q1
$13.7M Buy
422,009
+3,342
+0.8% +$105K 1% 13
2016
Q4
$12.9M Buy
418,667
+5,279
+1% +$161K 1.03% 12
2016
Q3
$13.3M Buy
413,388
+19,074
+5% +$638K 1.42% 11
2016
Q2
$13.2M Buy
394,314
+18,325
+5% +$585K 1.47% 11
2016
Q1
$10.6M Buy
375,989
+9,240
+3% +$264K 1.24% 12
2015
Q4
$11.2M Buy
366,749
+28,909
+9% +$909K 1.34% 11
2015
Q3
$10.1M Buy
337,840
+19,393
+6% +$622K 1.36% 9
2015
Q2
$10.1M Buy
318,447
+3,293
+1% +$107K 1.32% 10
2015
Q1
$10.4M Buy
315,154
+15,169
+5% +$482K 1.42% 9
2014
Q4
$8.87M Buy
299,985
+12,416
+4% +$356K 1.3% 11
2014
Q3
$8.07M Buy
287,569
+14,189
+5% +$398K 1.29% 8
2014
Q2
$7.7M Buy
273,380
+4,976
+2% +$142K 1.3% 10
2014
Q1
$8.18M Buy
268,404
+10,688
+4% +$319K 1.53% 9
2013
Q4
$7.49M Buy
257,716
+16,290
+7% +$474K 1.55% 8
2013
Q3
$6.58M Buy
241,426
+8,258
+4% +$225K 1.63% 8
2013
Q2
$6.2M Buy
+233,168
New +$6.44M 1.86% 8

Other funds holding PFE

FineMark National Bank & Trust's PFE Position: Q4 2025 in Review

FineMark National Bank & Trust reduced its Pfizer (PFE) stake by 0.2% in Q4 2025, selling an estimated $8.95K and leaving 179,519 shares worth $4.47M. The position accounts for 0.14% of the portfolio, ranked #127.

FineMark National Bank & Trust first reported a position in PFE in Q2 2013 and has held it in 51 quarters since. The position peaked at $25.3M in Q4 2021. 2,905 funds tracked by Wall St. Rank hold PFE as of Q4 2025.

  • FineMark National Bank & Trust held 179,519 shares of Pfizer worth $4.47M as of Q4 2025.
  • FineMark National Bank & Trust sold 355 Pfizer shares in Q4 2025, an estimated $8.95K.
  • Pfizer made up 0.14% of FineMark National Bank & Trust's portfolio in Q4 2025, its #127 holding.
  • FineMark National Bank & Trust first reported a position in Pfizer in Q2 2013 and has held it in 51 quarters since.
  • FineMark National Bank & Trust's Pfizer position peaked at $25.3M in Q4 2021.
  • 2,905 funds tracked by Wall St. Rank held Pfizer as of Q4 2025.

Based on FineMark National Bank & Trust's 13F filing for Q4 2025, filed 12 Feb 2026.